Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results

Key Points

• Avidity Biosciences beat quarterly expectations: The clinical-stage biotech reported an adjusted loss of $1.18 per share, better than the consensus loss estimate of $1.42, while revenue of $3.0 million exceeded estimates of $0.67 million.
• Shares rose 1.3% to $12.33 following the results. The stock remains well below its 52-week high of $16.77 and its 200-day moving average of $23.13.
• Analyst sentiment remains mixed: The consensus rating is “Hold,” despite a consensus price target of $63.85; ratings include one Strong Buy, four Buys, eleven Holds and one Sell.

Avidity Biosciences (NASDAQ:RNA - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($1.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.24, FiscalAI reports. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $0.67 million.

Avidity Biosciences Trading Up 1.3%

Shares of NASDAQ:RNA traded up $0.16 during mid-day trading on Thursday, reaching $12.33. The stock had a trading volume of 127,102 shares, compared to its average volume of 123,586. The company has a market cap of $210.97 million and a P/E ratio of -12.71. Avidity Biosciences has a 1 year low of $11.13 and a 1 year high of $16.77. The business's 50 day moving average price is $12.36 and its 200 day moving average price is $23.13.

Analysts Set New Price Targets

Several analysts have issued reports on RNA shares. Cantor Fitzgerald initiated coverage on shares of Avidity Biosciences in a research report on Thursday, June 18th. They set an "overweight" rating and a $25.00 price target for the company. Leerink Partners initiated coverage on Avidity Biosciences in a report on Friday, May 15th. They set an "outperform" rating for the company. Zacks Research raised Avidity Biosciences to a "hold" rating in a research report on Friday, June 19th. Weiss Ratings upgraded shares of Avidity Biosciences from a "sell (e-)" rating to a "sell (e)" rating in a research note on Monday, August 3rd. Finally, Wall Street Zen raised Avidity Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, May 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $63.85.

Institutional Trading of Avidity Biosciences

Institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new stake in shares of Avidity Biosciences in the 4th quarter worth about $689,000. Alberta Investment Management Corp purchased a new stake in Avidity Biosciences in the fourth quarter worth about $1,803,000. Mackenzie Financial Corp boosted its stake in shares of Avidity Biosciences by 14.9% during the fourth quarter. Mackenzie Financial Corp now owns 7,255 shares of the biotechnology company's stock valued at $522,000 after purchasing an additional 941 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Avidity Biosciences in the 4th quarter valued at $303,000. Finally, Voloridge Investment Management LLC bought a new position in Avidity Biosciences in the fourth quarter worth about $46,324,000.

Avidity Biosciences Company Profile

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company's proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company's lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source